TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07172893: A Non-Randomized Open Label Clinical Trial Evaluating DermaBind TL

Sponsor: HealthTech Wound Care · Phase: PHASE4 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 150 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$1,168,640

Rescue Site Savings

+$770,240

Unlock Full NCT07172893 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07172893 Rescue Dossier →